Why prescribe highly purified factor VIII and IX concentrates?
The aftermath of the HIV catastrophe and hepatitis virus transmission to hemophiliacs has been characterized by continuous efforts to improve the purity of factor VIII and factor IX concentrates, increasing sophistication of the virucidal methods used, and the introduction of recombinant factor VIII. The cost of hemophilia care is substantial and there is a large price difference between products depending on their purity; generally, the purer the concentrate, the higher the price. The use of expensive highly purified concentrates may be questioned if these products are not superior in terms of safety, efficacy or convenience. The properties of concentrates used in hemophilia care are discussed in this review, as are their safety and side effects. The available data do not clearly reveal any clinical difference between factor VIII concentrates, although the highly purified products may be of theoretical benefit. With regard to factor IX, purified products do not seem to carry any risk of the well-known thromboembolic complications which occur in certain situations after treatment with prothrombin complex concentrates.
Berntorp
E
E
Department for Coagulation Disorders, Malmö University Hospital, Sweden.
D004340:Drug Contamination / Q000191:economics; D005164:Factor IX / Q000009:adverse effects / Q000302:isolation & purification* / Q000592:standards; D005169:Factor VIII / Q000009:adverse effects / Q000302:isolation & purification* / Q000592:standards; D015658:HIV Infections / Q000635:transmission; D006467:Hemophilia A / Q000191:economics / Q000628:therapy; D006526:Hepatitis C / Q000635:transmission; D006801:Humans
D005169:Factor VIII; D005164:Factor IX